Journal article · 2026 · Open access

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Benjamin Galloway, Mark Lunt, Kath D. Watson, Narges Azadbakht, BSRBR-RA Contributors Group, Kimme Leanne Hyrich

Arthritis & Rheumatology · Published 9 July 2026 · DOI 10.1002/art.70272

Open full textCite this paper

In brief

“Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study” is a 2026 journal article by Zixing Tian and 8 co-authors, published in Arthritis & Rheumatology. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Arthritis & Rheumatology.

Citations
0
References
27
Authors
9

Abstract

OBJECTIVE: Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin-6 receptor inhibitors (IL-6Ri). METHODS: This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the National Cancer Registration and Analysis Service. People with RA initiating first JAKi or IL-6Ri without prior exposure to the comparator class were included. The primary analysis was ever-exposed model with first 90 days after treatment initiation excluded. Cox proportional hazards models estimated hazard ratios (HRs) with inverse probability of treatment weighting (IPTW) to adjust for confounding. Secondary analysis was receiving-treatment analysis. RESULTS: A total of 3,985 people with RA were included in primary analysis, with 116 first-ever NMSC recorded. The IPTW HR for JAKi versus IL-6Ri was 1.64 (95% confidence interval [CI] 0.85-3.17). The IPT-weighted absolute rate difference was 3.3 events per 1,000 person-years with JAKi versus IL-6Ri, which is around one additional NMSC event for every 307 patients who initiated JAKi rather than IL-6Ri and were observed for one year. In receiving-treatment analysis, 32 and 19 NMSC events occurred among patients actively receiving IL-6Ri and JAKi, with IPTW HR of 1.82 (95% CI 0.84-3.96). CONCLUSION: Initiation of JAKi was associated with a clinically small, plausibly higher NMSC risk than IL-6Ri, although not statistically significant over 3.3 years. Rheumatologists and patients should weigh the potential risk of NMSC against the benefits of disease control when considering treatment choices.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Tian, Z., Kearsley‐Fleet, L., Zhao, S. S., Galloway, J. B., Lunt, M., Watson, K. D., Azadbakht, N., BSRBR-RA Contributors Group, & Hyrich, K. L. (2026). Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.70272

MLA 9

Tian, Zixing, et al. “Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study.” Arthritis & Rheumatology, 2026. https://doi.org/10.1002/art.70272.

Chicago

Tian, Zixing, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Benjamin Galloway, Mark Lunt, Kath D. Watson, Narges Azadbakht, BSRBR-RA Contributors Group, and Kimme Leanne Hyrich. 2026. “Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study.” Arthritis & Rheumatology. https://doi.org/10.1002/art.70272.

Harvard

Tian, Z. et al. (2026) ‘Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study’, Arthritis & Rheumatology. doi:10.1002/art.70272.

IEEE

Z. Tian et al., “Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study,” Arthritis & Rheumatology, 2026, doi: 10.1002/art.70272.

BibTeX

@article{tian2026nonmelanoma,
  title     = {{Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study}},
  author    = {Tian, Zixing and Kearsley‐Fleet, Lianne and Zhao, Sizheng Steven and Galloway, James Benjamin and Lunt, Mark and Watson, Kath D. and Azadbakht, Narges and BSRBR-RA Contributors Group and Hyrich, Kimme Leanne},
  journal   = {Arthritis \& Rheumatology},
  year      = {2026},
  doi       = {10.1002/art.70272},
  url       = {https://doi.org/10.1002/art.70272}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • non-melanoma skin cancer
  • rheumatoid arthritis
  • JAK inhibitors
  • IL-6 receptor inhibitor
  • cancer risk
  • biologic therapy
  • drug safety
  • risk-benefit decision-making

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Tian, Z., Kearsley‐Fleet, L., Zhao, S. S., Galloway, J. B., Lunt, M., Watson, K. D., Azadbakht, N., BSRBR-RA Contributors Group, & Hyrich, K. L. (2026). Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.70272

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Arthritis & Rheumatology: sign in and open the full text from this page.

Who wrote this paper?

Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Benjamin Galloway, Mark Lunt, Kath D. Watson, Narges Azadbakht, BSRBR-RA Contributors Group, Kimme Leanne Hyrich.

What is the DOI of this paper?

10.1002/art.70272, permanently at https://doi.org/10.1002/art.70272. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.